<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2888">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04387968</url>
  </required_header>
  <id_info>
    <org_study_id>2020-A01414-35</org_study_id>
    <nct_id>NCT04387968</nct_id>
  </id_info>
  <brief_title>Epidemiological Study of the Covid-19 Presto Test - The &quot;COVIDOR&quot; Study</brief_title>
  <acronym>COVIDOR</acronym>
  <official_title>Epidemiological Study of the Covid-19 Presto Test Among Agents of the Local Authorities of CCTVL, Region Centre Val de Loire and Orleans Métropole. Correlation of IgM Level According to Contact With the Public</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Raphael Serreau</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>François Rabelais University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Paris</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Orléans Métropole Service de Médecine Préventive</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The &quot;COVIDOR&quot; epidemiological study. Our study would be the first at the community level in
      Orleans Métropole, aiming to determine the link between a positive IgM level on the
      serological test and a healthy carrier of covid-19 in agents in contact with the public. It
      would provide epidemiological surveillance of anti-covid-19 immunity in the community
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The metropolitan area of Orléans Métropole has 6,700 agents divided into 250 different trades
      and consequently multiple exposures and risks.

      The global covid-19 pandemic has affected France and the Loiret, the sarscov-2 coronavirus,
      has infected several thousand people. On May 7, 2020, there were 75 deaths at the CHRO
      hospital in Orleans, excluding EHPAD. The contamination rate of the population of the Loiret
      department has been estimated at 5.6% of the population by Public Health France. This rate is
      very low and does not allow the use of serological screening tests because of too many false
      positives or false negatives, there should be a prevalence of the disease greater than 60%.
      The French health authorities do not recommend the use of a screening test at the present
      time in view of the uncertainties of the results of this test. The Loiret Management Center,
      the Department and Orléans Métropole have decided to offer a covid-19 serological screening
      test, the covid-19 presto test, to voluntary territorial agents regardless of their return to
      work following the national &quot;deconfinement &quot;on May 11, 2020 This can only be done through an
      epidemiological surveillance study validated as part of a research protocol.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 24, 2020</start_date>
  <completion_date type="Anticipated">March 24, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 24, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Ecologic or Community</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Study the prevalence of Covid-19 infection, coronavirus (SARS coronavirus-2) in territorial agents in the 3 structures : CCTVL, Loire Valley Region Centre, Orleans Metropolitan city</measure>
    <time_frame>15 minutes</time_frame>
    <description>Covid-19 attack rate by measuring the frequency of anti-covid-19 IgM in each of the territorial structures</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine if there is a relationship between the profession carried out by the agents of the territorial community of Orleans metropolitan city, the Loire Valley Region, the CCTVL and contamination by covid-19</measure>
    <time_frame>6 months</time_frame>
    <description>Search for a correlation of covid-19 immunity based on the officer's position, if he is in contact with the public.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">5000</enrollment>
  <condition>Coronavirus Infection</condition>
  <arm_group>
    <arm_group_label>agents in contact with the public</arm_group_label>
    <description>patients working with children, policemen, desk office</description>
  </arm_group>
  <arm_group>
    <arm_group_label>agents with no contact with the public</arm_group_label>
    <description>administrative workers</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Covid-19 presto test</intervention_name>
    <description>Use an auto-test in 15 minutes get the results about covid-19 anticorps</description>
    <arm_group_label>agents in contact with the public</arm_group_label>
    <arm_group_label>agents with no contact with the public</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood drop to test IgM and IgG by an immunoserology rapid screening autotest
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Blood sample to be taken after self-bite. A consent form is given to the officer.

        A drop of blood is deposited on a coverslip, 2 drops of reagents allow migration to the
        gel.

        Reading in 15 minutes

          1. strip: negative result

          2. bands: positive result

        An authorized person, subject to medical confidentiality, reports the result in the medical
        file and informs the agent of the result.

        He is given a paper document signed by the SMP with the procedure to follow.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All the agents of the 3 local authorities (Loire Valley Region, CCTVL and Orléans
             Métropole) being voluntary to be tested for the COVID-PRESTO® test COVID-19 IgG / IgM
             rapid test (whole blood / serum / plasma) - Cassette

          -  Volunteer to get tested

        Exclusion Criteria:

          -  Opposition to the participation of the study

          -  Covid-19 disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pr Raphael SERREAU, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Orleans Metropole</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pr Raphael SERREAU, MD, PhD</last_name>
    <phone>0616386878</phone>
    <email>raphael.serreauurc@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Unité de Recherche PARADICT-O - Service de Médecine - Orléans Métropole</name>
      <address>
        <city>Orléans</city>
        <zip>45000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pr Raphaël O SERREAU, MD-PhD</last_name>
      <phone>0033238792437</phone>
      <email>raphael.serreau@orleans-metropole.fr</email>
    </contact>
    <contact_backup>
      <last_name>Hanane GUERROUT, MD</last_name>
      <phone>0033238792437</phone>
      <email>hanane.guerrout@orleans-metropole.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Raphaël SERREAU, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xavier MICHEL, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Pierre DURAND, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hanane GUERROUT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Unité de Recherche PARADICT-O - Service de Médecine - Orléans Métropole</name>
      <address>
        <city>Orléans</city>
        <zip>45000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Unité de Recherche PARADICT-O - Service de Médecine - O Métropole</last_name>
      <phone>0616386878</phone>
      <email>raphael.serreauurc@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Pr Raphael Serreau, MD, Phd</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>May 12, 2020</study_first_submitted>
  <study_first_submitted_qc>May 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 14, 2020</study_first_posted>
  <last_update_submitted>August 29, 2020</last_update_submitted>
  <last_update_submitted_qc>August 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Orléans Métropole Service de Médecine Préventive</investigator_affiliation>
    <investigator_full_name>Raphael Serreau</investigator_full_name>
    <investigator_title>Professeur Raphaël SERREAU (PU-PH)</investigator_title>
  </responsible_party>
  <keyword>covid-19</keyword>
  <keyword>serology</keyword>
  <keyword>depistage</keyword>
  <keyword>public health</keyword>
  <keyword>voluntary agents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Blood sample to be taken after self-bite. A consent form is given to the officer.
A drop of blood is deposited on a coverslip, 2 drops of reagents allow migration to the gel.
Reading in 15 minutes
strip: negative result
bands: positive result
An authorized person, subject to medical confidentiality, reports the result in the medical file and informs the agent of the result.
He is given a paper document signed by the SMP with the procedure to follow.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

